Ignite Creation Date:
2025-12-25 @ 1:31 AM
Ignite Modification Date:
2025-12-27 @ 11:21 PM
Study NCT ID:
NCT00517894
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2007-08-17
First Post:
2007-08-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Dose-Dense Therapy in Aggressive Lymphoma
Sponsor:
Arbeitsgemeinschaft medikamentoese Tumortherapie
Organization:
Study Overview
Official Title:
Phase 3 Study of Dose-Dense Therapy Versus CHOP in Aggressive Non-Hodgkin's Lymphoma
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2007-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate if a dose-dense chemotherapy with weekly chemotherapy compared to standard treatment every 3 weeks results in better survival in aggressive non-Hodgkin's lymphoma.
Detailed Description:
Patients are randomized to receive dose-dense CEOP/IMVP-Dexa chemotherapy or standard 3-weekly CHOP.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: